None listed
Conditions
Interventions
Drug, Radiation : 1. Experimental group: chemotherapy
[1] TC therapy
Paclitaxel (PTX): 175 mg/m2
intravenous infusion for 3 hours
Day 1
Carboplatin (CBDCA): AUC = 6.0
intravenous infusion for 1 hour
Day 1
6 times every 3 weeks (21 days)
[2] TP therapy
Paclitaxel (PTX): 175 mg/m2
Day 1
Cisplatin (CDDP): 50 mg/m2
intravenous infusion for 2 hours
Day 1
6 times every 3 weeks (21 days)
2. Control group: CCRT
Total pelvic dose: 50.4 Gy
Cisplatin (CDDP): 40 mg/m2
Day 1
Dosing weekly and repeat 5-6 times
Sponsors
Konkuk University Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1) Preoperative clinical stage IB1, IB2, IIA1, IIA2, or IIB cervical cancer 2) In case of histological diagnosis as follows from the tumor tissue after surgery - Squamous cell carcinoma (keratinizing type, nonkeratinizing type) - Adenocarcinoma (usual type of endocervical adenocarcinoma, intestinal type of mucinous carcinoma, endometrioid carcinoma) - Adenosquamous cell carcinoma 3) Pathologically confirmed pelvic lymph node metastasis or uterine chamber invasion from surgically resected tissue 4) In contrast-enhanced CT performed within 56 days before surgery, there should be no metastases other than pelvic lymph nodes (short diameter =10 mm) or distant metastases to the chest, upper abdomen, or pelvis, even when PET/CT was performed instead of contrast-enhanced CT Recognition. Simple CT is also permitted if it is difficult to use a contrast medium due to complications such as allergies or bronchial asthma. 5) There should be no lymph node metastasis other than the surgically resected pelvic lymph node. For invasive cancer, the incision should be negative. Intraepithelial lesions in the cut plane are acceptable. 6) Type III radical hysterectomy is performed by laparotomy or laparoscopy, and all of the following conditions must be met. - There should be no gross residual tumor and negative amputation - More than 20 pathologically confirmed pelvic lymph nodes - Ligamentum cardinal amputation - The vaginal incision (length from the vaginal fornix) measured before fixation is more than 2 cm - The operating surgeon must meet the following requirements ? Gynecologic oncology expert recognized by the Korea Society of Gynecologic Oncology ? Gynecological oncologist or obstetrician-gynecologist recognized by the Korea Society of Obstetrics and Gynecology 7) At the time of registration, age 20 or older, 75 or younger 8) General condition ECOG score 0 or 1 9) Within 42 days after surgery 10) Primary treatment (previously radiotherapy or prior chemotherapy is not allowed) 11) Normal function of major organs (bone marrow, heart, liver, kidney, etc.) In the inspection within 14 days before registration - Neutrophil count: =1,500/mm3 - Platelet count: =100,000/mm3 - Hemoglobin level: =10.0 g/dL (values ??after blood transfusion will be acceptable) - AST (GOT) and ALT (GPT): =100 IU/L - Total bilirubin: =1.5 mg/dL - Serum creatinine: =1.2 mg/dL - Ccr (Modified Jelliffe equation): =50 mL/min Modified Jlliffe equation Ccr (mL/min) = [98 - {0.8 * (Age - 20)}] / Serum creatinine (mg/dL) - ECG: Normal or minor changes not requiring treatment 12) When the consent form is signed
Exclusion criteria
Exclusion criteria: 1) Pathologically not completely resected (including positive amputation) 2) Aortic lymph node metastasis (short diameter =10 mm on pathological diagnosis or CT) 3) adnexal metastasis 4) peritoneal metastasis 5) Surgical water infection requiring systemic treatment 6) Serious comorbidities (liver/kidney/heart disease, myelosuppression, infection, etc.) 7) Intestinal insufficiency or intestinal obstruction 8) Bladder or rectal fistula 9) Diabetes mellitus that is being treated or not controlled by continuous insulin administration 10) Interstitial pneumonia or pulmonary fibrosis suspected on plain chest radiography or CT 11) Other cancers within 5 years of active or disease-free period. Intra-epithelial cancer or mucosal tumors that have been cured with local treatment are permitted. 12) History of serious drug hypersensitivity reaction 13) Contraindication to PTX, CBDCA or CDDP 14) ascites or pleural effusion requiring treatment 15) HBs antigen or HCV antibody positive 16) HIV antibody positive 17) During oral or intravenous systemic steroid treatment 18) If you have ever had a hypersensitivity reaction to Polysorbate 80, polyoxyethylene castor oil (Cremophor EL) (such as ciclosporin), or hydrogenated castor oil (such as vitamins for injection) 19) In case the lead researcher is judged to be ineligible
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival (OS) | — |
Secondary
| Measure | Time frame |
|---|---|
| Relapse-free Survival ;Incidence rate of adverse events;Quality of Life (QOL) | — |
Countries
Korea, Republic of
Contacts
Public ContactA Jin Lee
Konkuk University Medical Center
Outcome results
None listed